Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, announce that they have entered into a definitive merger agreement (the “Merger Agreement”). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ophthalmic assets, will bring significant value for our stockholders.”
Read the full article: Onconetix and Ocuvex Therapeutics Announce Execution of Definitive Merger Agreement //
Source: https://www.globenewswire.com/news-release/2025/07/16/3116362/0/en/Onconetix-and-Ocuvex-Therapeutics-announce-execution-of-definitive-merger-agreement.html